{ "ticker": "GSK", "cik": "0001131399", "company": "GSK plc", "business_type": "pharmaceutical", "schema_template": "standard (biopharma, IFRS): income statement as GSK presents it (turnover, cost of sales, gross profit, SG&A, R&D, royalty income, other operating income/expense, operating profit, finance income/expense, tax, profit attributable to shareholders and to non-controlling interests, EPS); balance sheet; cash flow; GSK's own non-IFRS measures (Core operating profit, Core EPS, free cash flow, total net debt) in a separate block; turnover by product group and region and segment profit as breakdowns", "reporting_currency": "GBP", "converted_to_usd": true, "units": "actual US dollars (not millions), translated from pounds sterling at the exchange rates GSK itself states for each period; per-share figures are per American Depositary Share (one ADS = two ordinary shares); share counts are ordinary shares (actual count); percentages are percent", "units_notes_seen": { "FY2025 Form 20-F consolidated income statement": "column heads 'Notes | 2025 \u00a3m | 2024 \u00a3m | 2023 \u00a3m'; EPS rows 'Basic/Diluted earnings per share (pence)'", "FY2025 Form 20-F consolidated balance sheet": "column heads 'Notes | 2025 \u00a3m | 2024 \u00a3m'", "FY2025 Form 20-F consolidated cash flow statement": "column heads 'Notes | 2025 \u00a3m | 2024 \u00a3m | 2023 \u00a3m'", "FY2025 Form 20-F Note 15 Earnings per share": "'Weighted average number of shares in issue | 2025 millions | 2024 millions | 2023 millions'", "FY2025 Form 20-F Note 16 Dividends": "'Dividend per share (pence) | Total dividend \u00a3m'", "FY2025 Form 20-F Note 6 Turnover and segment information": "'2025 \u00a3m | 2024 \u00a3m | 2023 \u00a3m'", "FY2025 Form 20-F Note 5 Exchange rates": "'US$/\u00a3' average and period end rates for 2025 | 2024 | 2023", "FY2025 Form 20-F Group financial review (Core results, free cash flow)": "'2025 \u00a3m | 2024 \u00a3m | 2023 \u00a3m'; Core EPS printed in pence (p)", "FY2025 Form 20-F Note 42 net debt": "'2025 \u00a3m | 2024 \u00a3m | 2023 \u00a3m'", "Q3 2026 Form 6-K income statement": "column heads 'Q3 2026 \u00a3m | Q3 2025 \u00a3m | 9 months 2026 \u00a3m | 9 months 2025 \u00a3m'; EPS printed in pence (p)", "Q3 2026 Form 6-K balance sheet": "column heads '30 September 2026 \u00a3m | 31 December 2025 \u00a3m'", "Q3 2026 Form 6-K cash flow statement": "'Cash flow statement nine months ended 30 September 2026'; column heads '9 months 2026 \u00a3m | 9 months 2025 \u00a3m'", "Q3 2026 Form 6-K cash generation table and free cash flow reconciliation": "column heads 'Q3 2026 \u00a3m | Q3 2025 \u00a3m | 9 months 2026 \u00a3m | 9 months 2025 \u00a3m'", "Q3 2026 Form 6-K weighted average number of shares": "'Q3 2026 millions | Q3 2025 millions | 9 months 2026 millions | 9 months 2025 millions'", "Q3 2026 Form 6-K Total to Core reconciliations": "'Total results \u00a3m | ... | Core results \u00a3m'; EPS in pence (p)", "Q3 2026 Form 6-K turnover and segment tables": "'Q3 2026 | Year to date' over '\u00a3m | AER% | CER% | \u00a3m | AER% | CER%'; segment table '\u00a3m' with AER/CER %", "Q3 2026 Form 6-K net debt analysis": "'30 September 2026 \u00a3m | 31 December 2025 \u00a3m'", "Q3 2026 Form 6-K exchange rates": "'Q3 2026 | Q3 2025 | YTD 2026 | YTD 2025 | 2025', 'Average rates' and 'Period-end rates', US$/\u00a3" }, "adjustments": { "splits_applied": [], "splits_note": "None applied. The share consolidation that accompanied the July 2022 demerger of Haleon predates every period in this record, and each filing's per-share figures are used as printed.", "adr_ratio": 2.0, "per_share_basis": "per American Depositary Share. The FY2025 Form 20-F cover lists 'American Depositary Shares, each representing 2 Ordinary Shares'; GSK prints per-share amounts in pence per ordinary share, so each is restated in pounds, doubled to one ADS and translated to US dollars.", "fx": "Reported in pounds sterling and translated to US dollars at the US$/\u00a3 rates GSK states: flows (income statement, cash flow, per-share amounts) at the period's average rate and balance-sheet positions at the period-end rate. FY2025 average 1.31 / year-end 1.35; FY2024 1.28 / 1.25; FY2023 average 1.24 (FY2025 Form 20-F, Note 5). Q3 2026 average 1.34 / 30 September 2026 period-end 1.33; Q3 2025 average 1.33; 9 months 2026 average 1.34; 9 months 2025 average 1.31 (Q3 2026 Form 6-K). The trailing-twelve-month figures, for which GSK states no rate, use the average of the Federal Reserve's daily US$/\u00a3 rates from 1 October 2025 to 30 September 2026 (about 1.341). The rate applied to each period is recorded on it under 'conversion'." }, "annual": [ { "fiscal_year": 2025, "label": "FY2025", "period_start": "2025-01-01", "period_end": "2025-12-31", "period_type": "fiscal year", "source_accession": "0001131399-26-000004", "accounting_basis": "IFRS (UK-adopted and as issued by the IASB); audited consolidated financial statements, Form 20-F", "conversion": { "currency": "GBP", "average": { "gbp_per_usd": 0.763359, "source": "FY2025 Form 20-F (accession 0001131399-26-000004), Note 5 'Exchange rates': average rate US$/\u00a3 1.31 for 2025; expressed here as pounds per US dollar (1/1.31)" }, "ads_ratio": 2.0, "closing": { "gbp_per_usd": 0.740741, "source": "FY2025 Form 20-F (accession 0001131399-26-000004), Note 5 'Exchange rates': period end rate US$/\u00a3 1.35 for 2025; expressed here as pounds per US dollar (1/1.35)" } }, "income_statement": { "revenue": 42793757590, "cost_of_sales": 11812266574, "gross_profit": 30981491015, "selling_general_and_administration": 11905276547, "research_and_development": 9857747141, "royalty_income": 1151489666, "other_operating_income_expense": 20959994, "operating_income": 10390916987, "finance_income": 221389936, "finance_expense": 918309734, "share_of_profit_of_associates_and_joint_ventures": 1310000, "profit_before_tax": 9695307188, "income_tax_expense": 1456719578, "net_income": 8238587611, "net_income_attributable_to_noncontrolling_interests": 750629782, "net_income_attributable_to_shareholders": 7487957828, "basic_eps": 3.6968, "diluted_eps": 3.6366, "basic_weighted_average_shares": 4051000000, "diluted_shares": 4117000000, "dividends_per_share": 1.7292 }, "balance_sheet": { "property_plant_and_equipment": 12584695595, "right_of_use_assets": 980099657, "goodwill": 9474296684, "other_intangible_assets": 22609792087, "total_non_current_assets": 58870779395, "inventories": 7997397201, "trade_and_other_receivables": 10085846470, "liquid_investments": 12149996, "cash_and_cash_equivalents": 4585948395, "total_current_assets": 23638491727, "total_assets": 82509271122, "short_term_borrowings": 4066198577, "contingent_consideration_liabilities_current": 1819799363, "trade_and_other_payables": 20764342732, "total_current_liabilities": 28877839893, "long_term_borrowings": 19855793050, "pensions_and_other_post_employment_benefits": 2277449203, "contingent_consideration_liabilities_non_current": 7269747456, "total_non_current_liabilities": 32090838768, "total_liabilities": 60968678661, "shareholders_equity": 22108942262, "noncontrolling_interests": -568349801, "total_equity": 21540592461, "total_borrowings": 23921991627 }, "cash_flow": { "cash_generated_from_operations": 11715326603, "taxation_paid": -1574619543, "operating_cash_flow": 10140707059, "capex": -1765879488, "purchase_of_intangible_assets": -2144469378, "purchase_of_businesses_net_of_cash_acquired": -2216519357, "net_cash_from_investing_activities": -5545228392, "repayment_of_long_term_loans": -1833999468, "issue_of_long_term_notes": 2592489248, "dividends_paid_to_shareholders": -3358839026, "purchase_of_treasury_shares": -1803869477, "net_cash_from_financing_activities": -4827348600 }, "non_ifrs": { "core_operating_profit": 12815726283, "core_eps_basic": 4.5064, "free_cash_flow_as_defined_by_gsk": 5277988469, "total_net_debt": 19511543171 }, "revenue_by_product_group": { "specialty_medicines": 17650934881, "vaccines": 11995666521, "general_medicines": 13147156187 }, "revenue_by_region": { "uk": 894729741, "us": 22085283595, "europe": 8973497398, "international": 10840246856 }, "segment_profit": { "commercial_operations": 21300593823, "research_and_development": -8188807625 } }, { "fiscal_year": 2024, "label": "FY2024", "period_start": "2024-01-01", "period_end": "2024-12-31", "period_type": "fiscal year", "source_accession": "0001131399-26-000004", "accounting_basis": "IFRS (UK-adopted and as issued by the IASB); audited consolidated financial statements, Form 20-F", "conversion": { "currency": "GBP", "average": { "gbp_per_usd": 0.78125, "source": "FY2025 Form 20-F (accession 0001131399-26-000004), Note 5 'Exchange rates': average rate US$/\u00a3 1.28 for 2024; expressed here as pounds per US dollar (1/1.28)" }, "ads_ratio": 2.0, "closing": { "gbp_per_usd": 0.8, "source": "FY2025 Form 20-F (accession 0001131399-26-000004), Note 5 'Exchange rates': period end rate US$/\u00a3 1.25 for 2024; expressed here as pounds per US dollar (1/1.25)" } }, "income_statement": { "revenue": 40161280000, "cost_of_sales": 11581440000, "gross_profit": 28579840000, "selling_general_and_administration": 14099200000, "research_and_development": 8193280000, "royalty_income": 817920000, "other_operating_income_expense": -1958400000, "operating_income": 5146880000, "finance_income": 156160000, "finance_expense": 856320000, "share_of_profit_of_associates_and_joint_ventures": -3840000, "profit_before_tax": 4450560000, "income_tax_expense": 673280000, "net_income": 3777280000, "net_income_attributable_to_noncontrolling_interests": 481280000, "net_income_attributable_to_shareholders": 3296000000, "basic_eps": 1.6179, "diluted_eps": 1.5923, "basic_weighted_average_shares": 4077000000, "diluted_shares": 4142000000, "dividends_per_share": 1.5616 }, "balance_sheet": { "property_plant_and_equipment": 11533750000, "right_of_use_assets": 1057500000, "goodwill": 8727500000, "other_intangible_assets": 19393750000, "total_non_current_assets": 53082500000, "inventories": 7086250000, "trade_and_other_receivables": 8545000000, "liquid_investments": 26250000, "cash_and_cash_equivalents": 4837500000, "total_current_assets": 21246250000, "total_assets": 74328750000, "short_term_borrowings": 2936250000, "contingent_consideration_liabilities_current": 1465000000, "trade_and_other_payables": 19168750000, "total_current_liabilities": 27121250000, "long_term_borrowings": 18296250000, "pensions_and_other_post_employment_benefits": 2330000000, "contingent_consideration_liabilities_non_current": 7635000000, "total_non_current_liabilities": 30850000000, "total_liabilities": 57971250000, "shareholders_equity": 17088750000, "noncontrolling_interests": -731250000, "total_equity": 16357500000, "total_borrowings": 21232500000 }, "cash_flow": { "cash_generated_from_operations": 10062080000, "taxation_paid": -1672960000, "operating_cash_flow": 8389120000, "capex": -1790720000, "purchase_of_intangible_assets": -2026240000, "purchase_of_businesses_net_of_cash_acquired": -1030400000, "net_cash_from_investing_activities": -1573120000, "repayment_of_long_term_loans": -2067200000, "issue_of_long_term_notes": 1376000000, "dividends_paid_to_shareholders": -3128320000, "purchase_of_treasury_shares": 0.0, "net_cash_from_financing_activities": -6049280000 }, "non_ifrs": { "core_operating_profit": 11709440000, "core_eps_basic": 4.0781, "free_cash_flow_as_defined_by_gsk": 3664640000, "total_net_debt": 16368750000 }, "revenue_by_product_group": { "specialty_medicines": 15116800000, "vaccines": 11696640000, "general_medicines": 13347840000 }, "revenue_by_region": { "uk": 906240000, "us": 20971520000, "europe": 7626240000, "international": 10657280000 }, "segment_profit": { "commercial_operations": 19628800000, "research_and_development": -7481600000 } }, { "fiscal_year": 2023, "label": "FY2023", "period_start": "2023-01-01", "period_end": "2023-12-31", "period_type": "fiscal year", "source_accession": "0001131399-26-000004", "accounting_basis": "IFRS (UK-adopted and as issued by the IASB); audited consolidated financial statements, Form 20-F", "conversion": { "currency": "GBP", "average": { "gbp_per_usd": 0.806452, "source": "FY2025 Form 20-F (accession 0001131399-26-000004), Note 5 'Exchange rates': average rate US$/\u00a3 1.24 for 2023; expressed here as pounds per US dollar (1/1.24)" }, "ads_ratio": 2.0 }, "income_statement": { "revenue": 37606701949, "cost_of_sales": 10620594902, "gross_profit": 26986107047, "selling_general_and_administration": 11637394414, "research_and_development": 7716516296, "royalty_income": 1181719433, "other_operating_income_expense": -450119784, "operating_income": 8363795985, "finance_income": 142599932, "finance_expense": 982079529, "share_of_profit_of_associates_and_joint_ventures": -6199997, "profit_before_tax": 7519356391, "income_tax_expense": 937439550, "net_income": 6581916841, "net_income_attributable_to_noncontrolling_interests": 471199774, "net_income_attributable_to_shareholders": 6110717067, "basic_eps": 3.0157, "diluted_eps": 2.9735, "basic_weighted_average_shares": 4052000000, "diluted_shares": 4111000000, "dividends_per_share": 1.4384 }, "cash_flow": { "cash_generated_from_operations": 10039035181, "taxation_paid": -1646719210, "operating_cash_flow": 8392315972, "capex": -1629359218, "purchase_of_intangible_assets": -1277199387, "purchase_of_businesses_net_of_cash_acquired": -1806679133, "net_cash_from_investing_activities": -1977799051, "repayment_of_long_term_loans": -2802398655, "issue_of_long_term_notes": 276519867, "dividends_paid_to_shareholders": -2786278663, "purchase_of_treasury_shares": 0.0, "net_cash_from_financing_activities": -6994836642 }, "non_ifrs": { "core_operating_profit": 10894634771 }, "revenue_by_product_group": { "specialty_medicines": 12702553903, "vaccines": 12231354129, "general_medicines": 12672793917 }, "revenue_by_region": { "uk": 859319588, "us": 19616790584, "europe": 7280036506, "international": 9850555272 }, "segment_profit": { "commercial_operations": 18173431277, "research_and_development": -6952676663 } } ], "quarterly": [ { "fiscal_year": 2026, "fiscal_quarter": 3, "label": "Q3 2026", "period_start": "2026-07-01", "period_end": "2026-09-30", "period_type": "three months", "source_accession": "0001654954-26-009181", "accounting_basis": "IFRS; unaudited condensed financial information in the Q3 2026 Results Announcement, Form 6-K", "conversion": { "currency": "GBP", "average": { "gbp_per_usd": 0.746269, "source": "Q3 2026 Results Announcement, Form 6-K (accession 0001654954-26-009181), 'Exchange rates and impact on results': average rate US$/\u00a3 1.34 for Q3 2026; expressed here as pounds per US dollar (1/1.34)" }, "ads_ratio": 2.0, "closing": { "gbp_per_usd": 0.75188, "source": "Q3 2026 Results Announcement, Form 6-K (accession 0001654954-26-009181), 'Exchange rates and impact on results': period-end rate US$/\u00a3 1.33 for 30 September 2026 (Q3 2026); expressed here as pounds per US dollar (1/1.33)" } }, "income_statement": { "revenue": 11908574522, "cost_of_sales": 3202598527, "gross_profit": 8705975995, "selling_general_and_administration": 3193218531, "research_and_development": 2657218778, "royalty_income": 345719841, "other_operating_income_expense": -351079839, "operating_income": 2850178689, "finance_income": 38859982, "finance_expense": 293459865, "share_of_profit_of_associates_and_joint_ventures": -2679999, "profit_before_tax": 2592898807, "income_tax_expense": 310879857, "net_income": 2282018950, "net_income_attributable_to_noncontrolling_interests": 214399901, "net_income_attributable_to_shareholders": 2067619049, "basic_eps": 1.0318, "diluted_eps": 1.0157, "basic_weighted_average_shares": 4009000000, "diluted_shares": 4073000000, "dividends_per_share": 0.4556 }, "balance_sheet": { "property_plant_and_equipment": 12543224983, "right_of_use_assets": 919029632, "goodwill": 10927275629, "other_intangible_assets": 33478746609, "total_non_current_assets": 71559291376, "inventories": 8378996648, "trade_and_other_receivables": 10936585625, "liquid_investments": 37239985, "cash_and_cash_equivalents": 3902218439, "total_current_assets": 23800340480, "total_assets": 95359631856, "short_term_borrowings": 2661328935, "contingent_consideration_liabilities_current": 1752939299, "trade_and_other_payables": 20791881683, "total_current_liabilities": 27557588977, "long_term_borrowings": 28860988456, "pensions_and_other_post_employment_benefits": 2064159174, "contingent_consideration_liabilities_non_current": 7063627175, "total_non_current_liabilities": 43380592648, "total_liabilities": 70938181625, "shareholders_equity": 24942810023, "noncontrolling_interests": -521359791, "total_equity": 24421450231, "total_borrowings": 31522317391 }, "non_ifrs": { "total_net_debt": 27582858967, "free_cash_flow_as_defined_by_gsk": 2784518719, "core_operating_profit": 4121838104, "core_profit_attributable_to_shareholders": 2933258651, "core_eps_basic": 1.4633 }, "cash_flow": { "cash_generated_from_operations": 4183478076, "operating_cash_flow": 3764058269, "capex": -501159769, "purchase_of_intangible_assets": -213059902 }, "revenue_by_product_group": { "specialty_medicines": 5195177610, "vaccines": 3461218408, "general_medicines": 3252178504 }, "revenue_by_region": { "us": 6607536961, "europe": 2583518812, "international": 2717518750 }, "segment_profit": { "commercial_operations": 6555276985, "research_and_development": -2394578898 } }, { "fiscal_year": 2025, "fiscal_quarter": 3, "label": "Q3 2025", "period_start": "2025-07-01", "period_end": "2025-09-30", "period_type": "three months", "source_accession": "0001654954-26-009181", "accounting_basis": "IFRS; unaudited condensed financial information in the Q3 2026 Results Announcement, Form 6-K", "conversion": { "currency": "GBP", "average": { "gbp_per_usd": 0.75188, "source": "Q3 2026 Results Announcement, Form 6-K (accession 0001654954-26-009181), 'Exchange rates and impact on results': average rate US$/\u00a3 1.33 for Q3 2025; expressed here as pounds per US dollar (1/1.33)" }, "ads_ratio": 2.0 }, "income_statement": { "revenue": 11367505453, "cost_of_sales": 3003138799, "gross_profit": 8364366654, "selling_general_and_administration": 2977868809, "research_and_development": 2246369101, "royalty_income": 276639889, "other_operating_income_expense": 31919987, "operating_income": 3448688621, "finance_income": 34579986, "finance_expense": 222109911, "share_of_profit_of_associates_and_joint_ventures": 5319998, "profit_before_tax": 3266478693, "income_tax_expense": 414959834, "net_income": 2851518859, "net_income_attributable_to_noncontrolling_interests": 174229930, "net_income_attributable_to_shareholders": 2677288929, "basic_eps": 1.3273, "diluted_eps": 1.3061, "basic_weighted_average_shares": 4034000000, "diluted_shares": 4102000000, "dividends_per_share": 0.4256 }, "cash_flow": { "cash_generated_from_operations": 3351598659, "operating_cash_flow": 2955258818, "capex": -413629835, "purchase_of_intangible_assets": -755439698 }, "non_ifrs": { "free_cash_flow_as_defined_by_gsk": 1657179337, "core_operating_profit": 3970048412, "core_profit_attributable_to_shareholders": 2948608821, "core_eps_basic": 1.463 }, "segment_profit": { "commercial_operations": 6003617599, "research_and_development": -1980369208 } } ], "year_to_date": { "label": "9 months 2026 (nine months ended 30 September 2026)", "period_start": "2026-01-01", "period_end": "2026-09-30", "period_type": "nine months", "source_accession": "0001654954-26-009181", "accounting_basis": "IFRS; unaudited condensed financial information in the Q3 2026 Results Announcement, Form 6-K", "prior_year_comparative": { "label": "9 months 2025 (nine months ended 30 September 2025)", "period_start": "2025-01-01", "period_end": "2025-09-30", "period_type": "nine months", "source_accession": "0001654954-26-009181", "accounting_basis": "IFRS; unaudited condensed financial information in the Q3 2026 Results Announcement, Form 6-K", "conversion": { "currency": "GBP", "average": { "gbp_per_usd": 0.763359, "source": "Q3 2026 Results Announcement, Form 6-K (accession 0001654954-26-009181), 'Exchange rates and impact on results': average rate US$/\u00a3 1.31 for YTD 2025; expressed here as pounds per US dollar (1/1.31)" }, "ads_ratio": 2.0 }, "income_statement": { "revenue": 31504180864, "cost_of_sales": 8331597584, "gross_profit": 23172583280, "selling_general_and_administration": 8448187550, "research_and_development": 6779248034, "royalty_income": 830539759, "other_operating_income_expense": 174229949, "operating_income": 8949917405, "finance_income": 170299951, "finance_expense": 672029805, "share_of_profit_of_associates_and_joint_ventures": 2619999, "profit_before_tax": 8450807549, "income_tax_expense": 1164589662, "net_income": 7286217887, "net_income_attributable_to_noncontrolling_interests": 631419817, "net_income_attributable_to_shareholders": 6654798070, "basic_eps": 3.2776, "diluted_eps": 3.2226, "basic_weighted_average_shares": 4062000000, "diluted_shares": 4129000000 }, "cash_flow": { "cash_generated_from_operations": 8192737624, "taxation_paid": -1036209699, "operating_cash_flow": 7156527925, "capex": -1015249706, "purchase_of_intangible_assets": -1552349550, "purchase_of_businesses_net_of_cash_acquired": -2168049371, "net_cash_from_investing_activities": -4322998746, "repayment_of_long_term_loans": -1836619467, "issue_of_long_term_notes": 2592489248, "dividends_paid_to_shareholders": -2512579271, "purchase_of_treasury_shares": -1473749573, "net_cash_from_financing_activities": -3705988925 }, "non_ifrs": { "free_cash_flow_as_defined_by_gsk": 4020388834, "core_operating_profit": 10675186904, "core_profit_attributable_to_shareholders": 7785327742, "core_eps_basic": 3.8331 }, "segment_profit": { "commercial_operations": 16427395236, "research_and_development": -5644788363 } }, "conversion": { "currency": "GBP", "average": { "gbp_per_usd": 0.746269, "source": "Q3 2026 Results Announcement, Form 6-K (accession 0001654954-26-009181), 'Exchange rates and impact on results': average rate US$/\u00a3 1.34 for YTD 2026; expressed here as pounds per US dollar (1/1.34)" }, "ads_ratio": 2.0 }, "income_statement": { "revenue": 33399484636, "cost_of_sales": 8751535974, "gross_profit": 24647948662, "selling_general_and_administration": 8983355868, "research_and_development": 9568935598, "royalty_income": 880379595, "other_operating_income_expense": -408699812, "operating_income": 6567336979, "finance_income": 146059933, "finance_expense": 761119650, "share_of_profit_of_associates_and_joint_ventures": -12059994, "profit_before_tax": 5940217268, "income_tax_expense": 452919792, "net_income": 5487297476, "net_income_attributable_to_noncontrolling_interests": 509199766, "net_income_attributable_to_shareholders": 4978097710, "basic_eps": 2.479, "diluted_eps": 2.4415, "basic_weighted_average_shares": 4015000000, "diluted_shares": 4079000000 }, "cash_flow": { "cash_generated_from_operations": 9886515452, "taxation_paid": -988919545, "operating_cash_flow": 8897595907, "capex": -1236819431, "purchase_of_intangible_assets": -946039565, "purchase_of_businesses_net_of_cash_acquired": -12390974300, "net_cash_from_investing_activities": -13350413859, "repayment_of_long_term_loans": -1964439096, "issue_of_long_term_notes": 10423855205, "dividends_paid_to_shareholders": -2749678735, "purchase_of_treasury_shares": -849559609, "net_cash_from_financing_activities": 3742618278 }, "non_ifrs": { "free_cash_flow_as_defined_by_gsk": 6548576988, "core_operating_profit": 11424834745, "core_profit_attributable_to_shareholders": 8159256247, "core_eps_basic": 4.0629 }, "revenue_by_product_group": { "specialty_medicines": 14585893290, "vaccines": 9401435675, "general_medicines": 9412155670 }, "revenue_by_region": { "us": 17387832002, "europe": 8111016269, "international": 7900636366 }, "segment_profit": { "commercial_operations": 18169051642, "research_and_development": -6399837056 } }, "trailing_twelve_months": { "label": "Twelve months ended 30 September 2026 (derived)", "period_start": "2025-10-01", "period_end": "2026-09-30", "period_type": "trailing twelve months", "source_accession": "0001654954-26-009181", "derived_from": [ "0001131399-26-000004", "0001654954-26-009181" ], "method": "FY2025 (Form 20-F) plus 9 months 2026 less 9 months 2025 (Q3 2026 Form 6-K), computed in pounds sterling and then translated to US dollars", "conversion": { "currency": "GBP", "average": { "gbp_per_usd": 0.745481, "source": "FRED DEXUSUK, average of 250 daily rates 2025-10-01 to 2026-09-30" } }, "income_statement": { "revenue": 44995110539, "operating_income": 8049836280, "net_income": 6468307039, "net_income_attributable_to_shareholders": 5836500192 }, "cash_flow": { "operating_cash_flow": 11962746200, "capex": -2006758053 }, "non_ifrs": { "core_operating_profit": 13628784637, "free_cash_flow_as_defined_by_gsk": 7843258245 } }, "notes": [ "Annual figures (FY2025, FY2024, FY2023) are from GSK's FY2025 annual report on Form 20-F (accession 0001131399-26-000004), prepared under IFRS. Quarterly (Q3 2026, Q3 2025) and nine-month figures are from the unaudited Q3 2026 Results Announcement furnished on Form 6-K on 28 October 2026 (accession 0001654954-26-009181).", "All money amounts are US dollars translated from pounds sterling at GSK's own stated exchange rates, which GSK prints to two decimal places. Because the rate differs between periods (for example US$1.33 per \u00a3 in Q3 2025 and US$1.34 in Q3 2026), dollar changes between periods combine business performance with exchange-rate movement and will not match GSK's own sterling (AER) or constant-currency (CER) growth rates.", "Per-share amounts (EPS, Core EPS, dividends per share) are per ADS, where one ADS is two ordinary shares. Share counts are ordinary shares. Diluted EPS ties to profit attributable to shareholders divided by diluted weighted average shares, multiplied by two.", "'net_income' is GSK's profit after taxation, which includes the share attributable to non-controlling interests (principally the minority holders in ViiV Healthcare); 'net_income_attributable_to_shareholders' is the EPS numerator.", "Expense lines (cost of sales, SG&A, R&D, finance expense, taxation) and liabilities are stored as positive amounts. Other operating income/(expense), share of associates and joint ventures, non-controlling interests (a deficit on GSK's balance sheet) and all cash-flow lines keep the filing's sign, so cash outflows are negative.", "Capex is purchase of property, plant and equipment. Purchase of intangible assets is shown separately. Total borrowings is short-term plus long-term borrowings as printed on the balance sheet; at 30 September 2026 this equals the \u00a323,701 million of gross debt the Q3 2026 results state.", "GSK's interim cash flow statement covers nine months only. The Q3 2026 and Q3 2025 cash figures (cash generated from operations, net cash from operating activities, purchase of property, plant and equipment, purchase of intangible assets) come from the same filing's cash generation table and free cash flow reconciliation, which print three-month columns. Quarterly investing and financing totals are not printed, so they are not shown.", "The balance sheet at 30 September 2026 is in the Q3 2026 entry. The results announcement does not print a 30 September 2025 balance sheet, so the Q3 2025 entry has none, and the Form 20-F presents balance sheets for 2025 and 2024 only, so FY2023 has none. The 31 December 2025 column in the Q3 2026 results matches the Form 20-F balance sheet line for line.", "The 'non_ifrs' block holds GSK's own measures. Core results exclude intangible asset amortisation and impairment, major restructuring and integration costs, transaction-related items (mainly remeasurement of the contingent consideration owed to Shionogi for the former Shionogi-ViiV Healthcare joint venture) and divestments, significant legal and other items. Core EPS is calculated on basic weighted average shares, as GSK reports it. Free cash flow follows GSK's definition: net cash from operating activities less capital expenditure on property, plant and equipment and intangible assets, contingent consideration payments in investing activities, net finance costs and distributions to non-controlling interests, plus contributions from non-controlling interests, proceeds from asset sales and dividends from associates and joint ventures. It is not operating cash flow minus capex. Total net debt, as GSK defines it, is total borrowings less cash, cash equivalents, liquid investments and certain short-term loans to third parties.", "Turnover by product group and region and segment profit are breakdowns as GSK presents them. The annual region table shows the UK separately from Europe, while the Q3 2026 results show only US, Europe and International, so the annual and interim 'europe' figures may not be defined alike. The results announcement prints prior-year quarter product and region turnover only as growth percentages, not amounts, so Q3 2025 and 9 months 2025 carry no product or region breakdown. Research and Development segment profit is a net cost and is negative.", "Dividends per share are those declared for each period (FY2025 66p, FY2024 61p, FY2023 58p per ordinary share; Q3 2026 17p and Q3 2025 16p), translated at the period's average rate. The dollar amount ADS holders actually receive is set at the exchange rate close to payment (for the Q3 2026 dividend, the rate on 5 January 2027) and is reduced by the depositary's fee.", "From 1 January 2026 GSK adopted amendments to IFRS 9 and IFRS 7 without restating comparatives. On transition, cash and cash equivalents rose by \u00a314 million, bank overdrafts fell by \u00a329 million and trade and other payables rose by \u00a343 million, and opening net debt was adjusted to \u00a314,410 million.", "Nine months 2026 figures reflect the acquisitions of Nuvalent (Q3 2026), RAPT Therapeutics (Q1 2026) and 35Pharma, with \u00a39,247 million paid for businesses net of cash acquired and \u00a37,779 million of long-term notes issued. R&D includes Q2 2026 impairments of \u00a31,334 million for camlipixant and \u00a3371 million related to the Alector collaboration, and Q3 2026 includes \u00a3328 million of major restructuring charges for the Accelerate Growth programme.", "The trailing-twelve-month view (twelve months ended 30 September 2026) is derived: FY2025 plus nine months 2026 less nine months 2025, computed in pounds and then translated." ], "uncertainties": [ "GSK states its exchange rates to two decimal places, so each translated dollar figure carries a rounding uncertainty of up to about 0.4%. The underlying sterling figures are exact as printed.", "The trailing-twelve-month figures are translated at a market average rate (about US$1.341 per \u00a3) rather than a rate GSK states, because GSK publishes none for that twelve-month window.", "Dividends per ADS in dollars are an approximation at the period's average rate; the amount actually paid depends on the exchange rate at payment." ], "headline": { "period": "Q3 FY2026", "period_end_words": "September 30, 2026", "metrics": [ { "label": "Revenue", "format": "usd", "value": 11908574522, "text": "$11.91 billion", "exact": "$11,908,574,522", "compact": "$11.91B", "abs": "$11.91 billion", "prior_value": 11367505453, "prior": "$11.37 billion", "priorabs": "$11.37 billion", "yoy": "up 4.8%", "source": { "array": "quarterly", "field": "income_statement.revenue", "index": 0, "period_label": "Q3 2026", "period_end": "2026-09-30", "period_start": "2026-07-01", "span_days": 91, "source_accession": "0001654954-26-009181", "prior_index": 1, "prior_period_label": "Q3 2025", "prior_period_end": "2025-09-30", "prior_period_start": "2025-07-01", "prior_span_days": 91, "prior_source_accession": "0001654954-26-009181", "gap_days": 365 } }, { "label": "Net income", "format": "usd", "value": 2067619049, "text": "$2.07 billion", "exact": "$2,067,619,049", "compact": "$2.07B", "abs": "$2.07 billion", "prior_value": 2677288929, "prior": "$2.68 billion", "priorabs": "$2.68 billion", "yoy": "down 22.8%", "source": { "array": "quarterly", "field": "income_statement.net_income_attributable_to_shareholders", "index": 0, "period_label": "Q3 2026", "period_end": "2026-09-30", "period_start": "2026-07-01", "span_days": 91, "source_accession": "0001654954-26-009181", "prior_index": 1, "prior_period_label": "Q3 2025", "prior_period_end": "2025-09-30", "prior_period_start": "2025-07-01", "prior_span_days": 91, "prior_source_accession": "0001654954-26-009181", "gap_days": 365 } }, { "label": "Diluted EPS", "format": "eps", "value": 1.0157, "text": "$1.02", "exact": "$1.02", "compact": "$1.02", "abs": "$1.02", "prior_value": 1.3061, "prior": "$1.31", "priorabs": "$1.31", "yoy": "down 22.2%", "source": { "array": "quarterly", "field": "income_statement.diluted_eps", "index": 0, "period_label": "Q3 2026", "period_end": "2026-09-30", "period_start": "2026-07-01", "span_days": 91, "source_accession": "0001654954-26-009181", "prior_index": 1, "prior_period_label": "Q3 2025", "prior_period_end": "2025-09-30", "prior_period_start": "2025-07-01", "prior_span_days": 91, "prior_source_accession": "0001654954-26-009181", "gap_days": 365 } }, { "label": "Core operating profit", "format": "usd", "value": 4121838104, "text": "$4.12 billion", "exact": "$4,121,838,104", "compact": "$4.12B", "abs": "$4.12 billion", "prior_value": 3970048412, "prior": "$3.97 billion", "priorabs": "$3.97 billion", "yoy": "up 3.8%", "source": { "array": "quarterly", "field": "non_ifrs.core_operating_profit", "index": 0, "period_label": "Q3 2026", "period_end": "2026-09-30", "period_start": "2026-07-01", "span_days": 91, "source_accession": "0001654954-26-009181", "prior_index": 1, "prior_period_label": "Q3 2025", "prior_period_end": "2025-09-30", "prior_period_start": "2025-07-01", "prior_span_days": 91, "prior_source_accession": "0001654954-26-009181", "gap_days": 365 } }, { "label": "Core EPS", "format": "eps", "value": 1.4633, "text": "$1.46", "exact": "$1.46", "compact": "$1.46", "abs": "$1.46", "prior_value": 1.463, "prior": "$1.46", "priorabs": "$1.46", "yoy": "flat", "source": { "array": "quarterly", "field": "non_ifrs.core_eps_basic", "index": 0, "period_label": "Q3 2026", "period_end": "2026-09-30", "period_start": "2026-07-01", "span_days": 91, "source_accession": "0001654954-26-009181", "prior_index": 1, "prior_period_label": "Q3 2025", "prior_period_end": "2025-09-30", "prior_period_start": "2025-07-01", "prior_span_days": 91, "prior_source_accession": "0001654954-26-009181", "gap_days": 365 } } ], "summary": "GSK plc reported revenue of $11.91 billion for Q3 FY2026, the quarter ended September 30, 2026, up 4.8% from a year earlier in US dollar terms, with Specialty Medicines again leading growth. Net income attributable to shareholders fell to $2.07 billion, down 22.8%, and diluted earnings were $1.02 per American Depositary Share, down 22.2%, as restructuring charges for GSK's new Accelerate Growth programme and lower other net operating income lowered reported operating profit against a year-ago quarter that had included the CureVac settlement. GSK's Core operating profit, the measure the company guides on, rose to $4.12 billion, up 3.8%, while Core earnings per American Depositary Share were $1.46, flat from a year earlier.", "qa": [ { "q": "How much revenue did GSK report in Q3 FY2026?", "a": "GSK plc reported revenue of $11.91 billion for Q3 FY2026, the quarter ended September 30, 2026, up 4.8% from $11.37 billion in the same quarter a year earlier in US dollar terms. GSK reports in pounds sterling, so the dollar change also reflects exchange-rate movement." }, { "q": "How much profit did GSK make in Q3 FY2026?", "a": "GSK plc reported net income attributable to shareholders of $2.07 billion for Q3 FY2026, the quarter ended September 30, 2026, down 22.8% from $2.68 billion a year earlier. The decline reflected lower reported operating profit, after restructuring charges for the Accelerate Growth programme and lower other net operating income, against a year-ago quarter that had included the CureVac settlement." }, { "q": "What were GSK's earnings per share in Q3 FY2026?", "a": "GSK plc reported diluted earnings of $1.02 per American Depositary Share for Q3 FY2026, the quarter ended September 30, 2026, down 22.2% from $1.31 a year earlier. GSK's Core earnings per American Depositary Share, which represents two ordinary shares, were $1.46, flat against the same quarter a year earlier." }, { "q": "What was GSK's core operating profit in Q3 FY2026?", "a": "GSK plc reported Core operating profit of $4.12 billion for Q3 FY2026, the quarter ended September 30, 2026, up 3.8% from $3.97 billion a year earlier in US dollar terms. Core results are the basis on which GSK gives its guidance." } ] }, "company_details": { "Name": "GSK plc", "Ticker": "GSK", "CIK": "0001131399", "Exchange": "NYSE", "State": "", "Country": "United Kingdom", "Incorporation": "United Kingdom", "SIC": "2834", "Office": "Life Sciences", "Industry": "Pharmaceutical Preparations" }, "next_filing": { "predicted_date": "2027-03-05", "predicted_type": "20-F" }, "fiscal_period": { "fiscal_year": 2026, "fiscal_period": "Q3", "tag": "FY26Q3", "period_end": "2026-09-30", "form": "6-K", "accession": "0001654954-26-009181", "fiscal_year_end": "1231", "source": "derived" }, "source_filings": [ { "role": "annual", "current": false, "form": "20-F", "fiscal_year": 2025, "fiscal_period": "FY", "tag": "FY25", "period_end": "2025-12-31", "filed": "2026-03-06", "accession": "0001131399-26-000004", "url": "https://www.sec.gov/Archives/edgar/data/1131399/000113139926000004/gsk-20251231.htm", "source": "reported" }, { "role": "quarterly", "current": true, "form": "6-K", "fiscal_year": 2026, "fiscal_period": "Q3", "tag": "FY26Q3", "period_end": "2026-09-30", "filed": "2026-10-28", "accession": "0001654954-26-009181", "url": "https://www.sec.gov/Archives/edgar/data/1131399/000165495426009181/0001654954-26-009181-index.htm", "source": "derived" } ], "figure_sources": { "about": "Where each figure in this file is printed in its SEC filing. This block mirrors the paths of the figures: figure_sources.annual[0].income_statement.net_income is the source of annual[0].income_statement.net_income. Each entry reads '#', and the link is documents[] + '#': it opens the filing at the line that prints that number. A figure with no entry is not printed in a tagged filing, either because it was calculated (margins, free cash flow, trailing twelve months, a quarter derived by subtraction) or because it comes from an untagged earnings release. A figure this file converted to US dollars links to the number as the filing prints it, in the filing's own currency: that number at its period's conversion rate (and ADS ratio, for a per-share figure) is the figure.", "documents": { "d1": "https://www.sec.gov/Archives/edgar/data/1131399/000113139926000004/gsk-20251231.htm" }, "annual": [ { "period_end": "2025-12-31", "income_statement": { "revenue": "d1#f-649", "cost_of_sales": "d1#f-72", "gross_profit": "d1#f-75", "selling_general_and_administration": "d1#f-78", "research_and_development": "d1#f-81", "royalty_income": "d1#f-84", "other_operating_income_expense": "d1#f-87", "operating_income": "d1#f-90", "finance_income": "d1#f-93", "finance_expense": "d1#f-96", "share_of_profit_of_associates_and_joint_ventures": "d1#f-4338", "profit_before_tax": "d1#f-105", "income_tax_expense": "d1#f-4335", "net_income": "d1#f-120", "net_income_attributable_to_noncontrolling_interests": "d1#f-114", "net_income_attributable_to_shareholders": "d1#f-117", "basic_eps": "d1#f-123", "diluted_eps": "d1#f-126", "basic_weighted_average_shares": "d1#f-1545", "diluted_shares": "d1#f-1551", "dividends_per_share": "d1#f-1580" }, "balance_sheet": { "property_plant_and_equipment": "d1#f-189", "right_of_use_assets": "d1#f-191", "goodwill": "d1#f-193", "other_intangible_assets": "d1#f-195", "total_non_current_assets": "d1#f-207", "inventories": "d1#f-209", "trade_and_other_receivables": "d1#f-2263", "liquid_investments": "d1#f-217", "cash_and_cash_equivalents": "d1#f-219", "total_current_assets": "d1#f-223", "total_assets": "d1#f-225", "short_term_borrowings": "d1#f-227", "contingent_consideration_liabilities_current": "d1#f-229", "trade_and_other_payables": "d1#f-231", "total_current_liabilities": "d1#f-241", "long_term_borrowings": "d1#f-243", "pensions_and_other_post_employment_benefits": "d1#f-247", "contingent_consideration_liabilities_non_current": "d1#f-253", "total_non_current_liabilities": "d1#f-257", "total_liabilities": "d1#f-259", "shareholders_equity": "d1#f-271", "noncontrolling_interests": "d1#f-273", "total_equity": "d1#f-275" }, "cash_flow": { "cash_generated_from_operations": "d1#f-465", "taxation_paid": "d1#f-468", "operating_cash_flow": "d1#f-471", "capex": "d1#f-474", "purchase_of_intangible_assets": "d1#f-480", "purchase_of_businesses_net_of_cash_acquired": "d1#f-495", "net_cash_from_investing_activities": "d1#f-522", "repayment_of_long_term_loans": "d1#f-528", "issue_of_long_term_notes": "d1#f-531", "dividends_paid_to_shareholders": "d1#f-1591", "purchase_of_treasury_shares": "d1#f-436", "net_cash_from_financing_activities": "d1#f-564" }, "non_ifrs": { "total_net_debt": "d1#f-917" }, "revenue_by_product_group": { "specialty_medicines": "d1#f-731", "vaccines": "d1#f-755", "general_medicines": "d1#f-764" }, "revenue_by_region": { "uk": "d1#f-771", "us": "d1#f-774", "europe": "d1#f-777", "international": "d1#f-780" }, "segment_profit": { "commercial_operations": "d1#f-799", "research_and_development": "d1#f-802" } }, { "period_end": "2024-12-31", "income_statement": { "revenue": "d1#f-650", "cost_of_sales": "d1#f-73", "gross_profit": "d1#f-76", "selling_general_and_administration": "d1#f-79", "research_and_development": "d1#f-82", "royalty_income": "d1#f-85", "other_operating_income_expense": "d1#f-88", "operating_income": "d1#f-91", "finance_income": "d1#f-94", "finance_expense": "d1#f-97", "share_of_profit_of_associates_and_joint_ventures": "d1#f-4339", "profit_before_tax": "d1#f-106", "income_tax_expense": "d1#f-4336", "net_income": "d1#f-121", "net_income_attributable_to_noncontrolling_interests": "d1#f-115", "net_income_attributable_to_shareholders": "d1#f-118", "basic_eps": "d1#f-124", "diluted_eps": "d1#f-127", "basic_weighted_average_shares": "d1#f-1546", "diluted_shares": "d1#f-1552", "dividends_per_share": "d1#f-1582" }, "balance_sheet": { "property_plant_and_equipment": "d1#f-190", "right_of_use_assets": "d1#f-192", "goodwill": "d1#f-194", "other_intangible_assets": "d1#f-196", "total_non_current_assets": "d1#f-208", "inventories": "d1#f-210", "trade_and_other_receivables": "d1#f-2264", "liquid_investments": "d1#f-218", "cash_and_cash_equivalents": "d1#f-220", "total_current_assets": "d1#f-224", "total_assets": "d1#f-226", "short_term_borrowings": "d1#f-228", "contingent_consideration_liabilities_current": "d1#f-230", "trade_and_other_payables": "d1#f-232", "total_current_liabilities": "d1#f-242", "long_term_borrowings": "d1#f-244", "pensions_and_other_post_employment_benefits": "d1#f-248", "contingent_consideration_liabilities_non_current": "d1#f-254", "total_non_current_liabilities": "d1#f-258", "total_liabilities": "d1#f-260", "shareholders_equity": "d1#f-272", "noncontrolling_interests": "d1#f-274", "total_equity": "d1#f-276" }, "cash_flow": { "cash_generated_from_operations": "d1#f-466", "taxation_paid": "d1#f-469", "operating_cash_flow": "d1#f-472", "capex": "d1#f-475", "purchase_of_intangible_assets": "d1#f-481", "purchase_of_businesses_net_of_cash_acquired": "d1#f-496", "net_cash_from_investing_activities": "d1#f-523", "repayment_of_long_term_loans": "d1#f-529", "issue_of_long_term_notes": "d1#f-532", "dividends_paid_to_shareholders": "d1#f-1592", "net_cash_from_financing_activities": "d1#f-565" }, "non_ifrs": { "total_net_debt": "d1#f-918" }, "revenue_by_product_group": { "specialty_medicines": "d1#f-732", "vaccines": "d1#f-756", "general_medicines": "d1#f-765" }, "revenue_by_region": { "uk": "d1#f-772", "us": "d1#f-775", "europe": "d1#f-778", "international": "d1#f-781" }, "segment_profit": { "commercial_operations": "d1#f-800", "research_and_development": "d1#f-803" } }, { "period_end": "2023-12-31", "income_statement": { "revenue": "d1#f-71", "cost_of_sales": "d1#f-74", "gross_profit": "d1#f-77", "selling_general_and_administration": "d1#f-80", "research_and_development": "d1#f-83", "royalty_income": "d1#f-86", "other_operating_income_expense": "d1#f-89", "operating_income": "d1#f-92", "finance_income": "d1#f-95", "finance_expense": "d1#f-98", "share_of_profit_of_associates_and_joint_ventures": "d1#f-4340", "profit_before_tax": "d1#f-107", "income_tax_expense": "d1#f-4337", "net_income": "d1#f-122", "net_income_attributable_to_noncontrolling_interests": "d1#f-116", "net_income_attributable_to_shareholders": "d1#f-119", "basic_eps": "d1#f-125", "diluted_eps": "d1#f-128", "basic_weighted_average_shares": "d1#f-1547", "diluted_shares": "d1#f-1553", "dividends_per_share": "d1#f-1584" }, "cash_flow": { "cash_generated_from_operations": "d1#f-467", "taxation_paid": "d1#f-470", "operating_cash_flow": "d1#f-473", "capex": "d1#f-476", "purchase_of_intangible_assets": "d1#f-482", "purchase_of_businesses_net_of_cash_acquired": "d1#f-497", "net_cash_from_investing_activities": "d1#f-524", "repayment_of_long_term_loans": "d1#f-530", "issue_of_long_term_notes": "d1#f-533", "dividends_paid_to_shareholders": "d1#f-1593", "net_cash_from_financing_activities": "d1#f-566" }, "revenue_by_product_group": { "specialty_medicines": "d1#f-733", "vaccines": "d1#f-757", "general_medicines": "d1#f-766" }, "revenue_by_region": { "uk": "d1#f-773", "us": "d1#f-776", "europe": "d1#f-779", "international": "d1#f-782" }, "segment_profit": { "commercial_operations": "d1#f-801", "research_and_development": "d1#f-804" } } ] } }